CAREDX INC. DL-,001 WKN: A118WG ISIN: US14167L1035 Kürzel: CDNA Forum: Aktien Thema: Hauptdiskussion

CareDx Announces $50 Million Stock Repurchase Program https://www.stocktitan.net/news/CDNA/care-dx-announces-50-million-stock-repurchase-0ojbl84wccp3.html?s=35

https://www.businesswire.com/news/home/20221111005229/en/CareDx-Committed-to-Delivering-Clinical-Innovation-to-the-Transplant-Patient-and-Physician-Community

CareDx GAAP EPS of -$0.06 beats by $0.33, revenue of $79.4M misses by $3.22M https://seekingalpha.com/news/3901313-caredx-gaap-eps-of-0_06-beats-0_33-revenue-of-79_4m-misses-3_22m • CareDx press release (NASDAQ:CDNA): Q3 GAAP EPS of -$0.06 beats by $0.33. • Revenue of $79.4M (+5.0% Y/Y) misses by $3.22M. • For the full year 2022, CareDx is revising our revenue expectations to be in the range of $320 million to $325 million due to lower Q3 revenue and a higher than anticipated shift in payer mix to commercial payors. • Full year consensus revenue estimate is $327.79M.

CareDx Reports Third Quarter 2022 Results https://www.benzinga.com/pressreleases/22/11/b29555287/caredx-reports-third-quarter-2022-results

https://www.businesswire.com/news/home/20221101005639/en/Independent-Longitudinal-Study-Finds-CareDx%E2%80%99s-AlloSure-Detects-Early-Signs-of-Rejection-in-Pediatric-Kidney-Transplant-Patients

Transplantationspatienten erleben weniger Schmerzen und weniger unerwünschte Ereignisse mit nicht-invasiven Testlösungen von CareDx https://www.businesswire.com/news/home/20220927005427/en/Transplant-Patients-Experience-Less-Pain-and-Fewer-Adverse-Events-with-CareDx-Non-Invasive-Testing-Solutions

CareDx Q2 results miss estimates, co revises FY 2022 revenue guidance https://seekingalpha.com/news/3867475-caredx-q2-results-miss-estimates-co-revises-fy-2022-revenue-guidance • CareDx press release (NASDAQ:CDNA): Q2 Non-GAAP EPS of -$0.13 misses by $0.02. • Revenue of $80.6M (+8.6% Y/Y) misses by $1.25M. • Sees FY 2022 revenue of $325 million to $335 million vs. previous forecast of $330M to $350M. The consensus revenue estimate is $337.96M. 

CareDx Reports Second Quarter 2022 Results https://www.businesswire.com/news/home/20220804005967/en/CareDx-Reports-Second-Quarter-2022-Results

CareDx Launches Personalized AlloHome Patient Monitoring Solution to Augment Pre- and Post-Transplant Care https://www.businesswire.com/news/home/20220802005596/en/CareDx-Launches-Personalized-AlloHome-Patient-Monitoring-Solution-to-Augment-Pre--and-Post-Transplant-Care AlloHome Alerts Healthcare Provider of Adverse Events to Drive Earlier Interventions

https://www.businesswire.com/news/home/20220602005408/en/CareDx-Leads-Transplant-Innovation-with-AiKidney-an-AI-Clinical-Decision-Support-Tool-for-Predicting-Allograft-Rejection-Risk

https://www.globenewswire.com/news-release/2022/05/24/2449070/31386/en/CareDx-Receives-CE-Mark-for-AlloSeq-HCT-for-Use-in-Hematopoietic-Cell-Transplantation.html

https://www.globenewswire.com/news-release/2022/05/17/2444754/31386/en/In-CareDx-Initiated-IP-Litigation-Against-Natera-Natera-Now-Drops-1-of-2-Patents-Originally-Asserted-Against-CareDx.html

CareDx Reports First Quarter 2022 Results https://www.globenewswire.com/news-release/2022/05/05/2437284/31386/en/CareDx-Reports-First-Quarter-2022-Results.html

https://www.globenewswire.com/news-release/2022/05/05/2436571/31386/en/CareDx-Validates-Clinical-Performance-of-AlloMap-Kidney-to-Comprehensively-Assess-Transplant-Rejection.html

https://www.globenewswire.com/news-release/2022/04/14/2422640/31386/en/CareDx-Reports-Over-200-000-Heart-Transplant-Patient-Results-Served.html CareDx Reports Over 200,000 Heart Transplant Patient Results Served CareDx Testing Services Have Been Used in Over 30,000 Heart Transplant Patients and Over 90 Percent of Centers in the United States

https://www.globenewswire.com/news-release/2022/04/11/2419896/31386/en/CareDx-the-Leading-Sponsor-of-UNOS-Transplant-Management-Forum-Demonstrates-the-Value-of-Digital-Solutions-to-Improve-Pre-Transplant-Patient-Referral-and-Waitlisting-Workflow.html